United Network for Organ Sharing (UNOS) policies allow for ABO-nonidentical liver transplantation (LT) in candidates with Model for End-Stage Liver Disease (MELD) scores greater than 30. Previous studies showed ABO-nonidentical LT resulted in an 18% and 55% net gain in livers for B and AB candidates. These results suggested that the current liver ABO allocation policies may need refinement. There are, however, strong associations between ABO blood groups and race/ethnicity. We hypothesized that race/ethnicity is associated with ABO-nonidentical LT and that this is primarily influenced by recipient ABO status. We examined non-status 1 adult candidates registered between July 1, 2013, and December 31, 2015. There were 27 835 candidates (70% non-Hispanic White, 15% Hispanic, 9% Black, 4% Asian, 1% Other/Multiracial).
| INTRODUCTION
. 1 Previous studies demonstrated that ABO-nonidentical LT, defined as both ABO compatible and ABO incompatible, resulted in a net gain of livers available for blood type B and AB LT waitlist candidates, on the magnitude of 18% and 55%, respectively. 3 In contrast, blood type O and A waitlist candidates are disadvantaged 4 with a total of 6% and 2% net loss in livers available to them, respectively, under the current allocation rules. 3 These results suggested that the current ABO allocation policies may require deliberate reconsideration to maintain equitable distribution of scarce organs.
Additional research, however, has also demonstrated that racial and ethnic minorities, specifically persons of Black and Asian race/ethnicities, represent a greater proportion of ABO blood types B and AB, the two blood types that receive a net gain in livers from ABO-nonidentical LT. 2 It follows that any refinement of the current ABO allocation policies may have a disproportionate effect on racial and ethnic minorities, some of whom were historically disadvantaged in transplantation medicine. 5, 6 We hypothesized that race/ethnicity is associated with ABO-nonidentical transplantation in the liver transplant candidate population-and that this association is largely explained by differences in ABO distribution among racial/ethnicity group, and not by any other clinical or demographic variables. In this study, therefore, we aimed to characterize the probability of ABOnonidentical LT by race/ethnicity.
| MATERIALS AND METHODS

| Subjects
We analyzed data from the UNOS/OPTN Standard Transplant 
| Data classifications
| Statistical analyses
Clinical characteristics and laboratory data were summarized by medians and interquartile ranges (IQR) for continuous variables or number T A B L E 1 UNOS/OPTN Policies 9.6.C and 9.6.D (%) for categorical variables. Comparisons between groups were performed using chi-square and Kruskal-Wallis tests, when appropriate.
The primary outcome was ABO-nonidentical LT. Patients who remained on the waitlist after December 31, 2015, who received living donor LT, and who were removed from the waiting list for nonmedical reasons (defined as "condition improved," "other," "refused transplant," "transferred to another center," and "unable to contact candidate") were censored from the analyses.
The risk of ABO-nonidentical transplantation was evaluated using the competing risks regression with the Fine-Gray model, with ABO-identical LT and death on the waitlist being treated as competing events. 12, 13 The covariables that we evaluated were race/ethnicity, age, sex, recipient ABO status, etiology of liver disease (categorized as chronic hepatitis C, alcohol, nonalcoholic fatty liver disease, autoimmune/cholestatic disease, chronic hepatitis B, and other), listing with exception points, laboratory MELD score at listing, listing center volume, and region of listing. All covariables in univariable analyses, regardless of P-value, were evaluated for inclusion in the final multivariable models to predict our outcome. We used purposeful selection of covariables in multivariable models to identify factors that may have confounded or mediated observed associations between race/ ethnicity and the outcome. Covariables that changed the coefficients of race/ethnicity by >20% after inclusion were considered strong confounders or mediators. 14 To determine the baseline level of disparities, we extended the multivariable methods described above to evaluate the risk of ABO-identical LT as well.
Cumulative incidence function (Nelson-Aalen) of ABO-nonidentical and ABO-identical LT by race/ethnicity was then calculated. Two-sided P values <.05 were considered statistically significant. Analyses were performed using STATA statistical software, version 13.0 (StataCorp, College Station, TX, USA). The institutional review board at the University of California, San Francisco, approved this study.
| RESULTS
| Characteristics of the waitlist cohorts
Baseline characteristics of the 27 835 candidates registered on the LT waitlist during the study period are displayed in Blacks were more likely to be listed at high-volume centers (68% vs 62% in non-Hispanic Whites).
T F I G U R E 1 Percentage of waitlist candidates transplanted at 6 months and at 1 year by race/ethnicity for all types of transplants
| ABO-nonidentical transplantation vs ABOidentical transplantation
A total of 11 369 patients underwent deceased donor LT: 10 556 (93%) were ABO identical, 662 (6%) were ABO compatible, and 151 (1%) were ABO incompatible ( were least likely to be transplanted at 6 months and at 1 year for all types of transplants ( Figure 1 ). The cumulative incidence of ABO-nonidentical and ABO-identical transplantations is shown in Figure 2A ,B, respectively.
| Associations between race/ethnicity and ABOnonidentical transplantation
In univariable competing risks analysis, Black and Asian race/ethnicity were associated with a significantly increased likelihood of
F I G U R E 2 (A) Cumulative hazard of ABO-nonidentical transplantation and (B) ABO-identical transplantation by race/ ethnicity
ABO-nonidentical LT ( We then examined the impact of recipient ABO blood group on the association between race/ethnicity and ABO-nonidentical LT. In our second multivariable model ( LT. These differences, however, were driven by the recipient's region of listing (eg, in "Low," "Medium," or "High" MELD regions) and not by the recipient's ABO status. Our study does show that Blacks had more severe liver disease than non-Hispanic Whites at the time of listing, which is consistent with previous research. 15, 16 Given that Blacks historically have had reduced access compared to non-Hispanic Whites for a number of medical therapies, including orthotopic LT, 16 the current ABO allocation policy represents an important mechanism for early access to orthotopic LT for historically disadvantaged racial/ethnic groups. LT. 22 The acceptability of A2 → O ABO-incompatible transplantation has also been independently demonstrated in Europe and Asia.
| DISCUSSION
23-25
When we analyzed the distribution of A2 → O transplantation, we This study has several limitations. First, this study relied on UNOS registry data for classification of race/ethnicity, so there is potential for misclassification of this predictor variable, as this variable was either self-reported or assessed by the transplant coordinator. However,
given that the proportion of race/ethnicities in our cohort paralleled previously reported distributions of race/ethnicities by ABO blood type, 2 we feel that misclassification of race/ethnicity did not occur on a large enough scale to significantly impact our results.
Second, large administrative registry analyses can be impacted by missing data; however, our primary predictors of interest included race/ethnicity and ABO blood type and our primary outcome included ABO-nonidentical LT, both of which were missing in less than 0.5% of observations. Lastly, this study only assessed patients who were listed and ultimately underwent LT, but does not allow for any definitive conclusions surrounding access to transplantation among minorities traditionally underserved by the healthcare system. 5, 6 Given our findings that Asians and Blacks, in particular, were advantaged by ABO-nonidentical LT, we suspect that these minority populations will be sensitive to any changes or refinements to the current ABO allocation policies. In the 2014 Kidney Allocation System, allocation of A2/A2B blood group kidneys to blood type B recipients has T A B L E 5 Multivariable models of the association between race/ethnicity and ABO-nonidentical transplantation resulted in greater access to kidneys by racial/ethnic minorities. 20, 21 Given this, it stands to reason that any changes to the current liver ABO allocation policy in this particular direction may further improve racial/ethnic minorities' access to LT.
Despite these limitations, our study raises important issues surrounding ABO-nonidentical LT by demonstrating the direct association between race/ethnicity with ABO-nonidentical transplantation. Any alterations to the current ABO allocation policy will most likely disproportionally impact Black and Asian candidates, who have been shown above to be the most likely to undergo ABO-nonidentical LT. Conversely, it is not for certain that alterations to the current policy would help candidates of other ethnic groups. Although UNOS Policy 9.6.C and 9.6.D
gives the transplant community a framework for ABO-nonidentical LT to occur, we currently still do not understand the most common cause for an ABO-nonidentical graft to be actively selected over an ABOidentical graft. This will be the focus of our next investigation.
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